Lilly Drops Inhaled Insulin With Alkermes; Will MannKind Make Giant Leap?
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Lilly is the third company to drop development of inhaled insulin, citing "increasing uncertainties in the regulatory environment" and evaluation of commercial and clinical potential. Novo Nordisk also dropped its fast-acting inhaled insulin AERx after Pfizer discontinued pioneer Exubera. MannKind CEO talks up advantages of its Technosphere product, still trying to make a go of the market